258 related articles for article (PubMed ID: 23071857)
1. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
3. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
4. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
5. What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
7. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells.
Fusi A; Reichelt U; Busse A; Ochsenreither S; Rietz A; Maisel M; Keilholz U
J Invest Dermatol; 2011 Feb; 131(2):487-94. PubMed ID: 20882037
[TBL] [Abstract][Full Text] [Related]
8. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
10. Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer.
Janikova M; Skarda J; Dziechciarkova M; Radova L; Chmelova J; Krejci V; Sedlakova E; Zapletalova J; Langova K; Klein J; Grygarkova I; Kolek V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Dec; 154(4):321-6. PubMed ID: 21293543
[TBL] [Abstract][Full Text] [Related]
11. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas.
Immervoll H; Hoem D; Sakariassen PØ; Steffensen OJ; Molven A
BMC Cancer; 2008 Feb; 8():48. PubMed ID: 18261235
[TBL] [Abstract][Full Text] [Related]
12. Significance of Expression of Cancer Stem Cell Markers CD133 and Nestin in Pancreatic Intraepithelial Carcinoma-invasive Adenocarcinoma Sequence.
Alshenawy HA
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):205-212. PubMed ID: 32197003
[TBL] [Abstract][Full Text] [Related]
13. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines.
Sana J; Zambo I; Skoda J; Neradil J; Chlapek P; Hermanova M; Mudry P; Vasikova A; Zitterbart K; Hampl A; Sterba J; Veselska R
Anal Cell Pathol (Amst); 2011; 34(6):303-18. PubMed ID: 22156015
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors.
Sabet MN; Rakhshan A; Erfani E; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000
[TBL] [Abstract][Full Text] [Related]
15. Nestin and other putative cancer stem cell markers in pancreatic cancer.
Matsuda Y; Kure S; Ishiwata T
Med Mol Morphol; 2012 Jun; 45(2):59-65. PubMed ID: 22718289
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma.
Liu J; Brown RE
Int J Clin Exp Pathol; 2010 Oct; 3(8):755-62. PubMed ID: 21151388
[TBL] [Abstract][Full Text] [Related]
17. The pathological characteristics of glioma stem cell niches.
He H; Li MW; Niu CS
J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
[TBL] [Abstract][Full Text] [Related]
18. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
19. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
[TBL] [Abstract][Full Text] [Related]
20. Latexin exhibits tumor-suppressor potential in pancreatic ductal adenocarcinoma.
Xue Z; Zhou Y; Wang C; Zheng J; Zhang P; Zhou L; Wu L; Shan Y; Ye M; He Y; Cai Z
Oncol Rep; 2016 Jan; 35(1):50-8. PubMed ID: 26530530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
